From mboxrd@z Thu Jan 1 00:00:00 1970 Return-Path: X-Spam-Checker-Version: SpamAssassin 3.1.3 (2006-06-01) on yquem.inria.fr X-Spam-Level: ** X-Spam-Status: No, score=2.0 required=5.0 tests=DATE_IN_FUTURE_06_12, HTML_MESSAGE,HTML_MIME_NO_HTML_TAG,MIME_HTML_ONLY autolearn=disabled version=3.1.3 Received: from mail1-relais-roc.national.inria.fr (mail1-relais-roc.national.inria.fr [192.134.164.82]) by yquem.inria.fr (Postfix) with ESMTP id 4FD3CBBCA for ; Mon, 17 Mar 2008 11:02:41 +0100 (CET) X-IronPort-Anti-Spam-Filtered: true X-IronPort-Anti-Spam-Result: At0sALLe3UfAXQIm/2dsb2JhbAA5ggYzAYxmgjKUYA X-IronPort-AV: E=Sophos;i="4.25,512,1199660400"; d="scan'208";a="9554422" Received: from discorde.inria.fr ([192.93.2.38]) by mail1-smtp-roc.national.inria.fr with ESMTP; 17 Mar 2008 11:02:41 +0100 Received: from mail3-relais-sop.national.inria.fr (mail3-relais-sop.national.inria.fr [192.134.164.104]) by discorde.inria.fr (8.13.6/8.13.6) with ESMTP id m2HA2eRd002917 (version=TLSv1/SSLv3 cipher=RC4-SHA bits=128 verify=OK) for ; Mon, 17 Mar 2008 11:02:41 +0100 X-IronPort-Anti-Spam-Filtered: true X-IronPort-Anti-Spam-Result: AtQfAPDe3UeTCEqEcmdsb2JhbAA5ggYzAYxmgSUBCQspT5Rf X-IronPort-AV: E=Sophos;i="4.25,512,1199660400"; d="scan'208";a="10349223" Received: from unknown (HELO ClinicalTrialMagnifier.com) ([147.8.74.132]) by mail3-smtp-sop.national.inria.fr with ESMTP; 17 Mar 2008 11:02:26 +0100 Received: from MIS-WW ([147.8.74.187]) by ClinicalTrialMagnifier.com with Microsoft SMTPSVC(6.0.3790.3959); Mon, 17 Mar 2008 13:39:26 +0800 From: "Johan PE Karlberg" Subject: Clinical Trial Magnifier, Issue 2 To: caml-list@inria.fr MIME-Version: 1.0 Date: Mon, 17 Mar 2008 21:39:26 +0000 Content-Type: text/html Content-Transfer-Encoding: quoted-printable Message-ID: X-OriginalArrivalTime: 17 Mar 2008 05:39:26.0929 (UTC) FILETIME=[437E7C10:01C887F1] X-Miltered: at discorde with ID 47DE41C0.001 by Joe's j-chkmail (http://j-chkmail . ensmp . fr)! X-Spam: no; 0.04; johan:01 johan:01 clinical:98 clinical:98 comprised:98 caml-list:01 data:02 hong:94 kong:91 feb:08 invited:09 university:10 analysis:11 monthly:87 newsletter:87

Dear Colleague (cam= l-list),

You are = invited to subscribe to a new free electronic monthly newsletter, the = Clinical Trial Magnifier at www.clinicaltrialmagnifier.com.=

The second Issue (= Feb 2008) - Sponsored Clinical Trial Globalization Trends
The a= nalysis data set comprised 5,167 industry-sponsored trials and 126,980= study sites. The United States, the "big five" European countries and= Canada continue to be leading trial locations worldwide, accounting f= or 3 out of 4 sites. Emerging countries with large populations includi= ng the four "BRIC" countries have become key sponsored clinical trial = countries. Established study site locations with small populations are= losing out in this globalization process, e.g. the four Scandinavian = countries.

Yours Si= ncerely

Johan PE= Karlberg, MD, PhD
Clinical Trials Centre
The University of Hong= Kong
P.S. If you have any kind of queries or messages please conta= ct me directly using:
editorialboard@clinicaltrialmagnifier.com =